The Leeuwenhoek Lecture, 1997: Marek's disease herpesvirus: oncogenesis and prevention
Open Access
- 29 December 1997
- journal article
- lecture
- Published by The Royal Society in Philosophical Transactions Of The Royal Society B-Biological Sciences
- Vol. 352 (1364) , 1951-1962
- https://doi.org/10.1098/rstb.1997.0181
Abstract
There are a number of neoplasias for which a herpesvirus is an essential part of the aetiology. Of these, Marek's disease is the most common and provides excellent opportunities for the study of a herpesvirus–induced tumour both experimentally and under natural conditions in the field. Marek's disease is caused by an alpha herpesvirus; it differs from the other oncogenic herpesviruses which are gamma herpesviruses. It is a ubiquitous virus in poultry populations of the world and is highly cell–associated and contagious, yet only a proportion of infected fowl develop tumours. Evidence is presented to suggest that at least one of the reasons for a wide variation in the incidence of the disease is a temporal interplay between virulent viruses and viruses of low or no virulence. The viral genes associated with the oncogenicity of Marek's disease virus (MDV) are discussed and it is concluded that it is likely that several genes are involved. Finally, a brief history of vaccination to control Marek's disease is given and mode of action discussed. It is concluded that the mechanism of protection is mainly through an antiviral cell mediated immune response, resulting in a lowered challenge virus burden. Marek's disease viruses over the past 40 years have been evolving greater oncogenicity, some of which are not adequately controlled by the vaccines that are currently available. It is suggested that for MDV to produce tumours, there is a need for the cytolytic infection phase and that infection must be with an MDV which possesses a functional gC , ICP4 for maintaining latency which allows the expression of at least the 1.8 kb family, pp38, meq , and possibly pp14 genes, for maintaining the tumour state and possibly initiating this state. Intervention in this process reduces the chance of tumour formation and incidence in a population which can occur through natural or man–mediated infection with non–pathogenic MDVs.Keywords
This publication has 96 references indexed in Scilit:
- Expression of Marek's disease virus (MDV) serotype 2 gene which has partial homology with MDV serotype 1 pp38 geneVirus Research, 1995
- Anti-idiotype antibodies to Marek's disease-associated tumour surface antigen in protection against Marek's diseaseVeterinary Immunology and Immunopathology, 1994
- Alterations in DNA sequence and RNA transcription of theBamHI-H fragment accompany attenuation of oncogenic Marek's disease herpesvirusVirus Genes, 1993
- Influence of serotype and virus strain on synergism between Marek's disease vaccine virusesAvian Pathology, 1992
- Nucleotide sequence of the Marek's disease virus (MDV) RB-1B A antigen gene and the identification of the MDV A antigen as the herpes simplex virus-1 glycoprotein C homologueVirus Research, 1989
- Demonstration of a marek's disease virus‐specific antigen in tumour lesions of chickens with marek's disease using monoclonal antibody against a virus phosphorylated proteinAvian Pathology, 1986
- Partial Protection against Marek's Disease in Chickens Immunized with Glycoproteins gB Purified from Turkey-Herpesvirus-Infected Cells by Affinity Chromatography Coupled with Monoclonal AntibodiesAvian Diseases, 1985
- Protection against Marek's Disease by Vaccination with a Herpesvirus of TurkeysPublished by JSTOR ,1970
- Immunization against Marek's Disease using a Live Attenuated VirusNature, 1969
- STUDIES ON FOWL PARALYSIS (NEUROLYMPHOMATOSIS GALLINARUM)The Journal of Experimental Medicine, 1929